Lupin has announced the commercial launch of its generic Sugammadex Injection in the United States following approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA). The launch further strengthens the company's injectable portfolio in the US pharmaceutical market.

The newly launched product is available in 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) single-dose vial presentations. Lupin's Sugammadex Injection is bioequivalent to Bridion Injection, the reference listed drug marketed by Merck Sharp & Dohme LLC.

Sugammadex Injection is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adult patients and paediatric patients aged two years and older undergoing surgical procedures.

The launch follows the US FDA's approval of Lupin's ANDA, enabling the company to offer a generic alternative to the branded therapy in one of the world's largest pharmaceutical markets.

Headquartered in Mumbai, India, Lupin is a global pharmaceutical company with a presence in more than 100 countries. The company develops and manufactures branded and generic formulations, complex generics, biotechnology products and active pharmaceutical ingredients (APIs), serving patients across multiple therapeutic areas worldwide.